News
Kamada raising investment to fund clinical trial of AAT
Globes online Israeli Business News
Biopharmaceutical company Kamada Ltd. today announced that it had expanded its latest round of fundraising with a NIS 6 million (Israeli Sheckels) investment from Meitav Provident and Pension Fund Ltd. and from Meitav Mishan Provident Fund Management Ltd.
Last week Kamada reported that it had raised $7 million from its founder Ralph Hahn and investment group UDT Med Holdings and that it was open to an additional $15 million in investments by June.
Kamada CEO David Tsur said that the company was conducting a kind of road show to Israeli institutional investors in order to raise investment to fund its upcoming and final clinical trial before marketing its Alpha-1 Antitrypsin (AAT) product for treating respiratory diseases.
